Ibrutinib Yields Durable Responses in CLL
Monotherapy with the investigational oral Bruton's tyrosine kinase inhibitor ibrutinib was well tolerated and produced durable responses in a phase Ib/II, open-label, multicenter study of 85 patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Lymphoma | Oral Cancer | Study